Browse > Article
http://dx.doi.org/10.6116/kjh.2022.37.3.41.

Inhibitory activity of Terminalia chebula extract against TNF-α/IFN-γ-induced chemokine increase on human keratinocyte, HaCaT cells  

Jo, Il-Joo (Central Stroke Center of Korean medicine, College of Korean Medicine, Wonkwang University)
Publication Information
The Korea Journal of Herbology / v.37, no.3, 2022 , pp. 41-47 More about this Journal
Abstract
Objectives : Terminalia chebula (TC) has been used as a traditional remedy to treat gastrointestinal infectious and inflammatory diseases. However, its protective effects and mechanisms against skin inflammation have not been well-elucidated. Thus, the aim of this study is to evaluate the protective effects of the TC water extract and also to suggest a putative mechanism of TC against skin injury on human keratinocytes, HaCaT cells. Methods : HaCaT cells were pre-treated with TC for 1 h and then stimulated with tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) (10 ng/mL each) to induce skin inflammation and injury. After 24 h, the cells were harvested to evaluate the expression of Th2 chemokines, such as C-C motif chemokine ligand 5 (CCL5, also known as RANTES), C-C chemokine ligand 17 (CCL17, also known as TARC) and C-C chemokine ligand 22 (CCL22, also known as MDC). To investigate the regulatory mechanisms of TC, we also assessed the phosphorylation of signal transducer and activator of transcription 1 (STAT1) signaling pathways in HaCaT cells. Results : Treatment of TC decreased the mRNA levels of RANTES, TARC and MDC with a concentration dependent manner against co-stimulation of TNF-α and IFN-γ. In addition, TC significantly reduced TNF-α and IFN-γ induced phosphorylation of STAT1. Conclusions : In summary, we propose that TC may be a promising candidate for anti-inflammatory skin protector through the inhibition of chemokines via STAT1 deactivation.
Keywords
Terminalia chebula; Skin inflammation; Keratinocyte; HaCaT cells; Chemokine;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Kang GJ, Dang HT, Han SC, Kang NJ, Koo DH, Koh YS, Hyun JW, Kang HK, Jung JH, Yoo ES. Methyl 5-chloro-4,5-didehydrojasmonate (J7) inhibits macrophage-derived chemokine production via down-regulation of the signal transducers and activators of transcription 1 pathway in HaCaT human keratinocytes. Chem Pharm Bull. 2013;61(10):1002-1008.   DOI
2 Pastore S, Mascia F, Girolomoni G. The contribution of keratinocytes to the pathogenesis of atopic dermatitis. Eur J Dermatol. 2006;16:125-131.
3 Kesharwani A, Polachira SK, Nair R, Agarwal A, Mishra NN, Gupta SK. Anti-HSV-2 activity of Terminalia chebula Retz extract and its constituents, chebulagic and chebulinic acids. BMC Complement Altern Med. 2017;17(1):110.   DOI
4 Malekzadeh F, Ehsanifar H, Shahamat M, Levin M, Colwell RR. Antibacterial activity of black myrobalan (Terminalia chebula Retz) against Helicobacter pylori. Int J Antimicrob Ag. 2001;18:85-88.   DOI
5 Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy. 2005;60(5):685-688.   DOI
6 Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, Andrew DP, Warnke R, Ruffing N, Kassam N, Wu L, Butcher EC. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature. 1999;400(6746):776-780.   DOI
7 Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N. Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis. Pediatr Allergy Immunol. 2008;19(7):605-613.   DOI
8 Benedetto AD, Kubo A, Beck LA. Skin barrier disruption: a requirement for allergen sensitization? J Invest Dermatol. 2012;132:949-963.   DOI
9 Qi XF, Kim DH, Yoon YS, Li JH, Song SB, Jin D, Huang XZ, Teng YC, Lee KJ. The adenylyl cyclase-cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF-kappaB in HaCaT keratinocytes. Mol Immunol. 2009;46(10):1925-1934.   DOI
10 Kovacic JC, Gupta R, Lee AC, Ma M, Fang F, Tolbert CN, Walts AD, Beltran LE, San H, Chen G, St Hilaire C, Boehm M. Stat3-dependent acute Rantes production in vascular smooth muscle cells modulates inflammation following arterial injury in mice. J Clin Invest. 2010;120(1):303-314.   DOI
11 Achari C, Reddy GV, Reddy TC, Reddanna P. Chebulagic acid synergizes the cytotoxicity of doxorubicin in human hepatocellular carcinoma through COX-2 dependant modulation of MDR-1. Med Chem. 2011;7:432-442.   DOI
12 Kim IR KH, Kuk YB, Park SJ, Park YK, Park JH, Seo BI, Seo YB, Shin MK, Lee YJ, LeeYC, Lee JH, Leem KH, Cho SI, Chung JK, Joo YS, Choi HY. Boncho-Hak. Seoul : Young-Lim Press. 2007 : 671-2.
13 Park JO. Effects of methanol extract from Terminalia chebulae on renal and pulmonary toxicities induced by paraquat in rats. J Life Sci 2008;8:129-135.   DOI
14 Lee KS, Kim SH, Sim KC, Park CS, Shin YS. Antimicrobial activity of Terminalia chebula Retz. extract of against intestinal pathogens. Korean J Food & Nutr 1997;10: 559-563.
15 Bag A, Kumar Bhattacharyya S, Kumar Pal N, Ranjan Chattopadhyay R. Anti-inflammatory, anti-lipid peroxidative, antioxidant and membrane stabilizing activities of hydroalcoholic extract of Terminalia chebula fruits. Pharm Biol. 2013;51(12):1515-1520.   DOI
16 Silawat N, Gupta VB. Chebulic acid attenuates ischemia reperfusion induced biochemical alteration in diabetic rats. Pharm Biol. 2013;51:23-29.   DOI
17 Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol. 2014;14:289-301.   DOI
18 Patil VS, Harish DR, Vetrivel U, Roy S, Deshpande SH, Hegde HV. Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from Terminalia chebula: A Structural Perspective. Molecules. 2022;27(3):1076.   DOI
19 Saleem A, Husheem M, Harkonen P, Pihlaja K. Inhbition of cancer cell growth by crude extract and the phenolics of Terminalia chebula Retz. fruit. J Ethnopharmacol. 2002;81:327-336.   DOI
20 Sabu MC, Kuttan R. Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. J Ethnopharmacol. 2002;81:155-160.   DOI
21 Abramovits W. Atopic dermatitis. J Am Acad Dermatol. 2005;53:86-93.
22 Jo IJ, Choi MO. Protective Effects of Kyungohkgo on Atopic Dermatitis in HaCaT Cells. J Kor Soc Cosmetol. 2020;27(5):1286-1292.
23 Wuthrich B. Epidemiology of the allergic diseases: are they really on the increase? Int Arch Allergy Appl Immunol. 1989;90:3-10.   DOI
24 Pivarcsi A, Homey B. Chemokine networks in atopic dermatitis: traffic signals of disease. Curr Allergy Asthma Rep. 2005;5(4):284-290.   DOI
25 Hudson TJ. Skin barrier function and allergic risk. Nat Genet. 2006;38(4):399-400.   DOI
26 Melik-Parsadaniantz S, Rostene W. Chemokines and neuromodulation. J Neuroimmunol. 2008;198(1-2):62-68.   DOI
27 Qi XF, Kim DH, Yoon YS, Li JH, Jin D, Teng YC, Kim SK, Lee KJ. Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-gamma in HaCaT cells, a human keratinocyte cell line. Br J Pharmacol. 2009;157:1441-1450.   DOI
28 Amarbayasgalan T, Takahashi H, Dekio I, Morita E. Interleukin-8 content in the stratum corneum as an indicator of the severity of inflammation in the lesions of atopic dermatitis. Int Arch Allergy Immunol. 2013;16(1)0:63-74.   DOI
29 Najjar I, Fagard R. STAT1 and pathogens, not a friendly relationship. Biochimie. 2010;92(5):425-444.   DOI
30 Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. J Dermatol Sci. 2006;43(2):75-84.   DOI
31 Akira S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells. 1999;17(3):138-146.   DOI
32 Han EH, Hwang YP, Choi JH, Yang JH, Seo JK, Chung YC, Jeong HG. Psidium guajava extract inhibits thymus and activationregulated chemokine (TARC/CCL17) production in human keratinocytes by inducing heme oxygenase-1 and blocking NF-kappaB and STAT1 activation. Environ Toxicol Pharmacol. 2011;32(2):136-145.   DOI
33 Ju SM, Song HY, Lee SJ, Seo WY, Sin DH, Goh AR, Kang YH, Kang IJ, Won MH, Yi JS, Kwon DJ, Bae YS, Choi SY, Park JS. Suppression of thymus-and activation-regulated chemokine (TARC/CCL17) production by 1,2,3,4,6-penta-O-galloyl-beta-D-glucose via blockade of NF-kappaB and STAT1 activation in the HaCaT cells. Biochem Biophys Res Commun. 2009;387(1):115-120.   DOI
34 Kwon DJ, Bae YS, Ju SM, Goh AR, Youn GS, Choi SY, Park J. Casuarinin suppresses TARC/CCL17 and MDC/CCL22 production via blockade of NF-kappaB and STAT1 activation in HaCaT cells. Biochem Biophys Res Commun. 2012;417(4):1254-1259.   DOI
35 Sung YY, Kim HK. Illicium verum extract suppresses IFN-gammainduced ICAM-1 expression via blockade of JAK/STAT pathway in HaCaT human keratinocytes. J Ethnopharmacol. 2013:149(3);626-632.   DOI
36 Hongqin T, Xinyu L, Heng G, Lanfang X, Yongfang W, Shasha S. Triptolide inhibits IFN-gamma signaling via the Jak/STAT pathway in HaCaT keratinocytes. Phytotherapy Research. 2011;25(11):1678-1685.   DOI
37 Jagtap AG, Karkera SG. Potential aqueous extract of Terminalia Chebula as an anticaries agent. J Ethnopharmocol. 1999;68:299-306.   DOI
38 Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol. 2002;14(1):129-135.   DOI
39 Kim WH, An HJ, Kim JY, Gwon MG, Gu H, Lee SJ, Park JY, Park KD, Han SM, Kim MK, Park KK. Apamin inhibits TNF-α-and IFN-γ-induced inflammatory cytokines and chemokines via suppressions of NF-κB signaling pathway and STAT in human keratinocytes. Pharmacol Rep. 2017;69(5):1030-1035.   DOI
40 Song TW, Sohn MH, Kim ES, Kim KW, Kim KE. Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis. Clin Exp Allergy. 2006;36(3):346-351.   DOI
41 Barker JN, Sarma V, Mitra RS, Dixit VM, Nickoloff BJ. Marked synergism between tumor necrosis factor-alpha and interferongamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest. 1990;85(2):605-608.   DOI